Veracyte, Inc. (VCYT)
| Market Cap | 3.49B +52.4% |
| Revenue (ttm) | 561.90M +17.3% |
| Net Income | 114.48M +334.7% |
| EPS | 1.39 +315.4% |
| Shares Out | 80.39M |
| PE Ratio | 31.38 |
| Forward PE | 24.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,684,009 |
| Open | 44.92 |
| Previous Close | 45.25 |
| Day's Range | 43.35 - 44.92 |
| 52-Week Range | 28.55 - 60.91 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 57.82 (+33.35%) |
| Earnings Date | Jul 30, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price target is $57.82, which is an increase of 33.35% from the latest price.
News
Cathie Wood’s ARK Investment buys 47.8K shares of Veracyte today
20:20 EDT Cathie Wood’s ARK Investment buys 47.8K shares of Veracyte (VCYT) today
Veracyte Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 saw strong revenue and margin performance, driven by new launches in breast cancer and MRD. Decipher remains a growth engine despite guideline headwinds, while Afirma and Prosigna benefit from operational and clinical advances. Strategic focus is on high-ROIC investments and international expansion.
Veracyte price target lowered to $44 from $47 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Veracyte (VCYT) to $44 from $47 and keeps an Underweight rating on the shares.
Veracyte price target lowered to $55 from $68 at Stephens
Stephens lowered the firm’s price target on Veracyte (VCYT) to $55 from $68 and keeps an Overweight rating on the shares. Shares sold off about 20% after the Q2 report…
Veracyte price target lowered to $54 from $66 at Piper Sandler
Piper Sandler lowered the firm’s price target on Veracyte (VCYT) to $54 from $66 following quarterly results. The firm keeps an Overweight rating on the shares.
Veracyte price target lowered to $50 from $60 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Veracyte (VCYT) to $50 from $60 and keeps a Hold rating on the shares. The firm said its target decrease…
Veracyte price target raised to $69 from $57 at Needham
Needham raised the firm’s price target on Veracyte (VCYT) to $69 from $57 and keeps a Buy rating on the shares after its Q2 earnings beat. Gross margin was up…
Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M
Consensus $585.45M. The company said, “The company is raising 2026 total revenue guidance to $590 million to $596 million, or 14% to 15% growth, from prior guidance of $582 to…
Veracyte reports Q2 EPS 54c, consensus 43c
Reports Q2 revenue $150.3M, consensus $144.48M. “Q2 was a milestone quarter for Veracyte (VCYT) as we launched two new products, Prosigna LDT and TrueMRD for MIBC, while also delivering strong…
Veracyte Earnings Call Transcript: Q2 2026
Q2 saw double-digit revenue and volume growth, driven by strong performance in Decipher and Afirma, and milestone launches of Prosigna LDT and TrueMRD. Raised full-year guidance reflects robust demand and operational execution, while ongoing investments support future growth.
Veracyte Earnings release: Q2 2026
Veracyte released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Veracyte Slides: Q2 2026
Veracyte has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Veracyte Quarterly report: Q2 2026
Veracyte has published its Q2 2026 quarterly earnings report on July 30, 2026.
Veracyte Announces Second Quarter 2026 Financial Results
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH...
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following inves...
Veracyte initiated with an Overweight at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of Veracyte (VCYT) with an Overweight rating and $66 price target The firm views Veracyte as a “rare cash generative” diagnosis lab, supported...
Veracyte price target raised to $60 from $42 at Canaccord
Canaccord raised the firm’s price target on Veracyte (VCYT) to $60 from $42 and keeps a Hold rating on the shares. The firm updated its model ahead of Q2 results…
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 af...
Veracyte price target raised to $47 from $37 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Veracyte (VCYT) to $47 from $37 and keeps an Underweight rating on the shares. The firm is updating its model ahead of…
Veracyte price target raised to $65 from $45 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Veracyte (VCYT) to $65 from $45 and keeps a Buy rating on the shares. The firm adjusted models and forecasts…
Veracyte Transcript: AGM 2026
The meeting confirmed quorum, elected all nominated directors, ratified the auditor, approved executive compensation, and passed an amendment to the equity incentive plan. No questions were submitted, and caution was advised regarding forward-looking statements.
Veracyte Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 results drove raised guidance, with double-digit growth in Afirma and Decipher, and EBITDA margins above target. New launches, including Prosigna and TrueMRD, are supported by robust clinical data and a disciplined investment approach. Market expansion is driven by innovation, data strategy, and operational efficiency.
Veracyte Transcript: 46th Annual William Blair Growth Stock Conference
Significant growth and innovation were highlighted, including the launch of Prosigna and TrueMRD, both backed by robust clinical evidence. Financial performance exceeded targets, with strong profitability and a positive outlook for 2026. Prosigna's OPTIMA data is seen as practice-changing.